CGTLive®’s Weekly Rewind – June 6, 2025

News
Article

Review top news and interview highlights from the week ending June 6, 2025.

CGTLive®’s Weekly Rewind

CGTLive®’s Weekly Rewind

Welcome to CGTLive®’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field.

1. Satri-cel Makes Strides in Gastric and Gastroesophageal Junction Cancer

The CAR T-cell therapy showed promise in treating advanced gastric cancer by demonstrating improved survival rates and safety in pivotal trial results.

2. Laura Aguilar MD, PhD, on Evaluating Immunotherapy DOC1021 for Glioblastoma

The chief medical officer of Diakonos Oncology discussed phase 1 data on the company’s autologous dendritic cell immunotherapy.

3. CD19/20-Targeted KITE-363 Elicits Strong Response in LBCL

KITE-363 shows promising results in treating relapsed/refractory large B-cell lymphoma, with high response rates and manageable adverse events.

4. Shahzad Raza, MD, on Evaluating CAR-T NXC-201 in R/R Light Chain Amyloidosis

The hematologist/oncologist at the Cleveland Clinic discussed early results from a clinical trial evaluating the BCMA-directed CAR-T therapy.

5. Iovance Biotherapeutics’ Lifileucel Produces Durable Responses in 5-Year Analysis of Advanced Melanoma Data

The analysis included 153 patients with a median follow-up of 57.8 months.

Recent Videos
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center
Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology
Sarah Hein, PhD, the chief executive officer and cofounder of March Biosciences
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Kiran Musunuru, MD, PhD, a physician-scientist and Barry J. Gertz Professor for translational research in the Perelman School of Medicine at the University of Pennsylvania and CHOP and Rebecca Ahrens-Nicklas, MD, PhD, a physician-scientist and director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program at CHOP
Cure SMA Treatment Recommendations
Related Content
FDA Activity Recap: May 2025 Features BLA Acceptance in MPS II, AdComm Announcement for DMD Cell Therapy, and More

FDA Activity Recap: May 2025 Features BLA Acceptance in MPS II, AdComm Announcement for DMD Cell Therapy, and More

Noah Stansfield
June 6th 2025
Article

Catch up on any of the key FDA news stories you may have missed last month, with coverage highlights from the CGTLive® team.

ImmunoLogic Episode 4

ImmunoLogic, Episode 4: "Inflammatory Storms and Gentle Balances: Navigating Toxicities in Immunotherapies" With Caroline Diorio, MD, FRCPC, FAAP

Joseph A. Fraietta, PhD;Janna Minehart, MD;Caroline Diorio, MD, FRCPC, FAAP;Noah Stansfield;Matt Hoffman
May 29th 2025
Podcast

In Episode 4 of ImmunoLogic, Caroline Diorio, MD, FRCPC, FAAP, discussed her research on adverse events associated with cell therapy.

Iovance Biotherapeutics’ Lifileucel Produces Durable Responses in 5-Year Analysis of Advanced Melanoma Data

Iovance Biotherapeutics’ Lifileucel Produces Durable Responses in 5-Year Analysis of Advanced Melanoma Data

Noah Stansfield
June 3rd 2025
Article

The analysis included 153 patients with a median follow-up of 57.8 months.

ImmunoLogic

ImmunoLogic, Episode 3: "Breaking the Brain’s Barrier: CAR T-Cells Take on Glioblastoma" With Marcela Maus, MD, PhD

Joseph A. Fraietta, PhD;Janna Minehart, MD;Marcela V. Maus, MD, PhD;Noah Stansfield;Matt Hoffman
April 8th 2025
Podcast

In Episode 3 of ImmunoLogic, Marcela Maus, MD, PhD, discussed her research on CAR-T for treating glioblastoma.

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology

The Potential to Apply Immunotherapy DOC1021 to a Broad Array of Tumor Types

Laura Aguilar MD, PhD;Noah Stansfield
June 2nd 2025
Article

Laura Aguilar MD, PhD, the chief medical officer of Diakonos Oncology discussed the broader implications of a positive data readout from a trial for the company’s autologous dendritic cell immunotherapy.

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center

Using a Digital App to Aid Caregivers for Patients Undergoing Hematopoietic Stem Cell Transplant

Jamie Jacobs, PhD;Noah Stansfield
June 2nd 2025
Article

Jamie Jacobs, PhD, the program director of the center for psychiatric oncology & behavioral sciences at Mass General Cancer Center, discussed her presentation at ASCO this year.

© 2025 MJH Life Sciences

All rights reserved.